AMTI: AI 评分 45/100 — AI 分析 (4月 2026)

Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company focused on developing oral and respiratory biologics for autoimmune, inflammatory, and metabolic diseases. Their lead product candidate, AMT-101, is currently in Phase II clinical trials for ulcerative colitis.

Key Facts: Price: $0.26 AI Score: 45/100 Sector: Healthcare

公司概况

概要：

Applied Molecular Transport (AMTI) pioneers oral biologic therapies, targeting autoimmune and inflammatory diseases with its GI-selective technology, offering a novel approach to treatment and positioning it for growth in the biopharmaceutical sector despite current financial challenges.

AMTI是做什么的？

Applied Molecular Transport Inc. (AMTI) is a clinical-stage biopharmaceutical company founded in 2010 and headquartered in South San Francisco, California. The company is dedicated to the design and development of a pipeline of oral and respiratory biologic product candidates aimed at treating autoimmune, inflammatory, metabolic, and other diseases. AMTI's innovative approach focuses on creating therapies that can be administered orally or through inhalation, potentially offering patients a more convenient and accessible alternative to traditional injectable biologics. The company's technology platform enables the development of various oral biologic therapeutic modalities, including peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Their lead product candidate, AMT-101, is a gastrointestinal (GI) selective oral fusion of recombinant human interleukin-10 (rhIL-10) currently in Phase II clinical trials for the treatment of ulcerative colitis and related inflammatory indications. Additionally, AMTI is developing AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. AMTI's focus on oral biologics represents a significant shift in the treatment paradigm for various diseases, potentially improving patient compliance and outcomes.

AMTI的投资论点是什么？

Investing in Applied Molecular Transport Inc. (AMTI) presents a high-risk, high-reward opportunity. The company's innovative GI-selective oral biologic platform has the potential to disrupt the treatment landscape for autoimmune and inflammatory diseases. The Phase II clinical trials for AMT-101 in ulcerative colitis represent a key value driver, with positive data potentially leading to significant stock appreciation. Further, the advancement of AMT-126 into later-stage trials could unlock additional value. However, the company's current market capitalization of $0.01 billion and negative P/E ratio of -0.08 highlight the inherent risks associated with investing in early-stage biopharmaceutical companies. Success hinges on clinical trial outcomes and the ability to secure future funding.

AMTI在哪个行业运营？

Applied Molecular Transport Inc. operates in the competitive biotechnology industry, which is characterized by high R&D costs, lengthy development timelines, and regulatory hurdles. The market for autoimmune and inflammatory disease treatments is substantial, with a growing demand for more convenient and effective therapies. AMTI's focus on oral biologics positions it to potentially capture a significant share of this market. Competitors like ALNA, APGN, BTHE, CHRO, and GLS are also vying for market share, but AMTI's unique GI-selective technology could provide a competitive edge. The biotechnology industry is expected to continue growing, driven by advancements in drug discovery and personalized medicine.

Biotechnology

Healthcare

AMTI有哪些增长机遇？

Expansion of AMT-101 into additional indications: Beyond ulcerative colitis, AMT-101 has the potential to treat other inflammatory bowel diseases (IBD) and autoimmune conditions. The market for IBD treatments is projected to reach billions of dollars, offering a significant growth opportunity for AMTI if clinical trials are successful and regulatory approvals are obtained. Timeline: 2-5 years for further clinical development and potential commercialization in new indications.
Advancement of AMT-126 through clinical trials: Successful completion of Phase I and subsequent clinical trials for AMT-126 could unlock a new market for treating diseases related to intestinal epithelium barrier function defects. This represents a significant growth driver, as there is a growing understanding of the role of the gut microbiome in overall health and disease. Timeline: 3-7 years for clinical development and potential commercialization.
Development of novel oral biologic therapies: AMTI's technology platform allows for the development of a wide range of oral biologic therapies, including peptides, proteins, antibodies, and RNA therapeutics. This provides a long-term growth opportunity as the company can expand its pipeline and target new disease areas. The market for biologic therapies is rapidly growing, driven by their effectiveness in treating complex diseases. Timeline: Ongoing, with new product candidates entering preclinical and clinical development.
Strategic partnerships and collaborations: AMTI can leverage its technology platform and clinical pipeline to form strategic partnerships with larger pharmaceutical companies. These partnerships can provide funding for further development and commercialization, as well as access to larger markets. The pharmaceutical industry is increasingly relying on collaborations to access innovative technologies and expand their product portfolios. Timeline: Ongoing, with potential for new partnerships in the near future.
Out-licensing of technology: AMTI could out-license its GI-selective technology to other companies for use in their own drug development programs. This would generate revenue for AMTI and validate the value of its platform. The market for drug delivery technologies is substantial, with companies seeking innovative ways to improve the efficacy and safety of their therapies. Timeline: Ongoing, with potential for out-licensing agreements in the coming years.

AMT-101 is in Phase II clinical trials for ulcerative colitis, representing a near-term value inflection point.
AMT-126 is in Phase I clinical trials for diseases related to intestinal epithelium barrier function defects, expanding the pipeline.
The company's GI-selective oral biologic platform offers a differentiated approach to drug delivery.
Market Cap of $0.01B reflects the early-stage nature and associated risks.
Beta of 2.29 indicates high volatility compared to the market.

AMTI提供哪些产品和服务？

Develop oral biologic therapies for autoimmune and inflammatory diseases.
Utilize a proprietary GI-selective technology platform.
Conduct clinical trials to evaluate the safety and efficacy of their product candidates.
Target diseases such as ulcerative colitis and other inflammatory bowel diseases.
Design and develop various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics.
Seek regulatory approval for their therapies from agencies like the FDA.

AMTI如何赚钱？

Develop and patent novel oral biologic therapies.
Conduct clinical trials to demonstrate efficacy and safety.
Seek regulatory approval for commercialization.
Potentially partner with larger pharmaceutical companies for manufacturing and distribution.

Patients suffering from autoimmune and inflammatory diseases.
Healthcare providers who prescribe and administer treatments.
Pharmaceutical companies interested in licensing or acquiring their technologies.
Potential partners for co-development and commercialization.

Proprietary GI-selective technology platform.
Patent protection for their product candidates and technologies.
Clinical data demonstrating the efficacy and safety of their therapies.
Expertise in developing oral biologic therapies.

什么因素可能推动AMTI股价上涨？

Upcoming: Phase II clinical trial results for AMT-101 in ulcerative colitis.
Upcoming: Initiation of Phase II clinical trials for AMT-101 in other inflammatory bowel diseases.
Ongoing: Advancement of AMT-126 through Phase I clinical trials.
Ongoing: Potential for strategic partnerships and collaborations.
Ongoing: Continued development of novel oral biologic therapies.

AMTI的主要风险是什么？

Potential: Clinical trial failures for AMT-101 or AMT-126.
Potential: Regulatory delays or rejection of their product candidates.
Ongoing: Competition from established pharmaceutical companies with greater resources.
Ongoing: Difficulty in raising capital to fund ongoing operations.
Potential: Intellectual property challenges or infringement.

AMTI的核心优势是什么？

Proprietary GI-selective technology platform.
Lead product candidate in Phase II clinical trials.
Experienced management team.
Focus on oral biologics, a growing market segment.

AMTI的劣势是什么？

Limited financial resources.
High reliance on clinical trial outcomes.
Early-stage company with no approved products.
Small number of employees (13).

AMTI有哪些机遇？

Expansion into new indications for AMT-101.
Advancement of AMT-126 and other pipeline candidates.
Strategic partnerships with larger pharmaceutical companies.
Out-licensing of technology.

AMTI面临哪些威胁？

Clinical trial failures.
Regulatory hurdles.
Competition from established pharmaceutical companies.
Difficulty in raising capital.

AMTI的竞争对手是谁？

Allena Pharmaceuticals Inc — Focuses on enzyme therapeutics for metabolic disorders. — (ALNA)
Apogee Therapeutics Inc — Develops antibody therapies for inflammatory and immunological diseases. — (APGN)
Bio-Path Holdings Inc — Develops RNAi nanoparticle drugs for cancer. — (BTHE)
Chromadex Corp — Focuses on dietary supplements and ingredients. — (CHRO)
Galectin Therapeutics Inc — Develops therapies for liver diseases and cancer. — (GLS)

Key Metrics

Price: $0.26 (-3.13%)
Market Cap: $12.0M
MoonshotScore: 45/100

Company Profile

CEO: Shawn M. Cross
Headquarters: South San Francisco, CA, US
Employees: 13
Founded: 2020

AI Insight

常见问题

What does Applied Molecular Transport Inc. do?

Applied Molecular Transport Inc. (AMTI) is a clinical-stage biopharmaceutical company focused on developing oral biologic therapies for autoimmune, inflammatory, and metabolic diseases. They utilize a proprietary GI-selective technology platform to deliver biologics directly to the site of disease in the gastrointestinal tract. Their lead product candidate, AMT-101, is currently in Phase II clinical trials for ulcerative colitis. AMTI aims to provide more convenient and effective treatments for patients by replacing injectable biologics with oral alternatives.

Is AMTI stock a good buy?

AMTI stock is a speculative investment with significant risks and potential rewards. The company's innovative technology and promising clinical pipeline offer upside potential, but the company's low market cap ($0.01B) and negative P/E ratio (-0.08) reflect the inherent risks of investing in early-stage biopharmaceutical companies. Positive clinical trial results for AMT-101 could drive significant stock appreciation, but clinical trial failures or regulatory setbacks could negatively impact the stock price. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing in AMTI.

What are the main risks for AMTI?

The main risks for AMTI include clinical trial failures, regulatory hurdles, competition from established pharmaceutical companies, and difficulty in raising capital. Clinical trial failures for AMT-101 or AMT-126 would significantly impact the company's value. Regulatory delays or rejection of their product candidates could also hinder their progress. AMTI faces competition from larger pharmaceutical companies with greater resources. The company's ability to raise capital to fund ongoing operations is also a key risk factor. These risks are typical for small biotech companies.